JP2007045829A5 - - Google Patents

Download PDF

Info

Publication number
JP2007045829A5
JP2007045829A5 JP2006229517A JP2006229517A JP2007045829A5 JP 2007045829 A5 JP2007045829 A5 JP 2007045829A5 JP 2006229517 A JP2006229517 A JP 2006229517A JP 2006229517 A JP2006229517 A JP 2006229517A JP 2007045829 A5 JP2007045829 A5 JP 2007045829A5
Authority
JP
Japan
Prior art keywords
igfbp
amino acid
binding agent
specific binding
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006229517A
Other languages
English (en)
Japanese (ja)
Other versions
JP4467549B2 (ja
JP2007045829A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007045829A publication Critical patent/JP2007045829A/ja
Publication of JP2007045829A5 publication Critical patent/JP2007045829A5/ja
Application granted granted Critical
Publication of JP4467549B2 publication Critical patent/JP4467549B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006229517A 1999-01-06 2006-08-25 インシュリン様成長因子（ｉｇｆ）ｉ変異体 Expired - Lifetime JP4467549B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11501099P 1999-01-06 1999-01-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005038688A Division JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Publications (3)

Publication Number Publication Date
JP2007045829A JP2007045829A (ja) 2007-02-22
JP2007045829A5 true JP2007045829A5 (enExample) 2007-04-05
JP4467549B2 JP4467549B2 (ja) 2010-05-26

Family

ID=22358799

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000592320A Withdrawn JP2002535967A (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2005038688A Withdrawn JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2006229517A Expired - Lifetime JP4467549B2 (ja) 1999-01-06 2006-08-25 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000592320A Withdrawn JP2002535967A (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2005038688A Withdrawn JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Country Status (12)

Country Link
US (6) US6506874B1 (enExample)
EP (1) EP1141015B1 (enExample)
JP (3) JP2002535967A (enExample)
AU (1) AU762047B2 (enExample)
CA (1) CA2356257C (enExample)
CY (1) CY1109452T1 (enExample)
DE (1) DE60042550D1 (enExample)
DK (1) DK1141015T3 (enExample)
ES (1) ES2329220T3 (enExample)
IL (3) IL143834A0 (enExample)
PT (1) PT1141015E (enExample)
WO (1) WO2000040612A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069177A1 (en) * 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
CA2356109C (en) * 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
AUPQ585500A0 (en) * 2000-02-25 2000-03-16 Gropep Pty Ltd Treatment for peripheral sensory neuropathy
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
AU2006203889A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. CRIPTO binding molecules
US20080103457A1 (en) * 2005-01-11 2008-05-01 Heart Failure Technologies, Inc. University Enterprise Laboratories (Uel) Method and System for Treating Heart Failure
TWI406870B (zh) * 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
FR2892174B1 (fr) 2005-10-14 2007-12-28 Vallourec Mannesmann Oil Gas F Element filete tubulaire muni d'un revetement protecteur sec
CN101484469B (zh) * 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
AU2009231394B2 (en) * 2008-04-03 2013-09-05 F. Hoffmann-La Roche Ag Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders
KR20100119899A (ko) * 2008-04-03 2010-11-11 에프. 호프만-라 로슈 아게 폴리에틸렌글리콜화된 인슐린 유사 성장 인자 분석법
EP2341940A1 (en) * 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
EP2328607A1 (en) * 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
WO2010094906A1 (en) * 2009-07-16 2010-08-26 Arecor Limited The stabilisation of proteins
US8759299B2 (en) * 2009-07-22 2014-06-24 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
CA2773428A1 (en) * 2009-09-10 2011-03-17 Lonza Biologics Plc Method and system for polypeptide purification
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
ES2674567T3 (es) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
HUE039033T2 (hu) 2012-01-10 2018-12-28 Biogen Ma Inc Terápiás molekulák transzportjának fokozása a vér-agy gáton keresztül
EP3626735A1 (en) * 2012-12-18 2020-03-25 Novartis AG Stabilized insulin-like growth factor polypeptides
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
EP3254104B1 (en) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
SG11201706293XA (en) 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
EP3453722A1 (en) * 2017-09-06 2019-03-13 Julius-Maximilians-Universität Würzburg Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
AU627423B2 (en) 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DE3850995T2 (de) 1987-04-23 1995-03-16 Monsanto Co Sekretion eines dem Insulin ähnlichen Wachstumsfaktors in E. coli.
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
JP2507106B2 (ja) * 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
ATE86496T1 (de) * 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
DE3854842T2 (de) 1988-04-12 1996-06-13 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69218948T2 (de) 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
SG46612A1 (en) * 1992-12-02 1998-02-20 Hoechst Ag Process for obtaining proinsulin in processing correctly linked cystine bridges
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
CA2224859A1 (en) 1996-04-17 1997-10-23 Amitabh Gaur Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
US6428781B1 (en) 1996-12-27 2002-08-06 Daiichi Pharmaceutical Co., Ltd. Composition of an endogenous insulin-like growth factor-II derivative
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2000069901A2 (en) 1999-05-19 2000-11-23 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes

Similar Documents

Publication Publication Date Title
DK2390265T3 (da) Insulinotropisk peptidderivat med modificeret N-terminal aminosyre
SMT201500015B (it) Composizione farmaceutica comprendente (1S)-1,5-anidro-1-[5-(4-etossibenzil)-2- metossi-4-metilfenil]-1-tio-d-glucitolo e un secretagogo dell'insulina
LTPA2017029I1 (lt) Rekombinantinis FSH, įskaitant alfa 2,3- ir alfa 2,6-sialilinimą
PE20090711A1 (es) Region constante de anticuerpo mutante
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
DK1983849T3 (da) Fødevaresammensætning omfattende aminosyrer
DK2035447T3 (da) Polypeptid
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
JP2010539123A5 (enExample)
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
WO2007060117A3 (de) Chimäre keratinbindende effektorproteine
PL2004160T3 (pl) Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
FR2900332B1 (fr) Composition dentaire en deux parties.
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
GB0503434D0 (en) Amyloid-binding peptides, analogues and uses thereof
DK1838341T3 (da) Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
ATE546152T1 (de) Bakteriocin-vermittler-peptide
NL1031705A1 (nl) Aminozuurderivaten.
FR2881348B1 (fr) Composition cosmetique nettoyante sous forme solide
GB0704352D0 (en) "Peptide, compositions and uses thereof"
PL2176282T3 (pl) 8-beta-podstawione 16.alfa.-fluoroestratrieny jako wybiórczo działające estrogeny
FR2894980B1 (fr) Compositions aqueuses epaissantes et limpides, leur utilisation dans des formulations aqueuses acides, formulations obtenues.
DK1971571T3 (da) Anvendelse af 3-(4-hydroxyphenyl)propionsyreamid i fremstillingen af anti-ældningssammensætninger
ZA201004800B (en) Compound (r)-n*6*-ethyl-6,7-dihydro-5h-indeno(5,6-d)thiazole-2,6-diamine and the use as antipsychotics
JP2012501322A5 (enExample)